Bio-Rad has diagnostics exposure, but the market may be questioning whether the segment deserves a peer-growth multiple.
Bio-Rad Laboratories: Is The Clinical Diagnostics Segment Underpriced Relative To Growth Peers?
NYSEBIOStock ResearchProof Gate
Thesis summary
Bio-Rad has diagnostics exposure, but the market may be questioning whether the segment deserves a peer-growth multiple.
View article
Discuss the thesis
0 commentsCommenting requires active membershipBecome a member
Attack the thesis, not the person.Add evidence when challenging claims.No pump, spam, or low-effort comments.
No comments yet. Start the discussion with evidence, a question, or a bear case.